IMPORTANCE Meta-analyses of treatments for posttraumatic stress disorder (PTSD) suggest that trauma-focused psychotherapies produce greater benefits than antidepressant medications alone.
C linical practice guidelines for posttraumatic stress disorder (PTSD) have presented both trauma-focused psychotherapies and selective serotonin reuptake inhibitors (SSRIs) as effective, strongly recommended treatments. [1] [2] [3] The American Psychological Association 4 and the Veterans Affairs (VA) and Department of Defense recommended traumafocused psychotherapy vs medication for the treatment of PTSD 1 based on meta-analyses comparing effect sizes across studies that rarely involved direct head-to-head comparisons of psychotherapy vs medication. 5, 6 Without direct comparisons, effect sizes across studies may not accurately reflect efficacy, owing to differences in study designs and comparators. Furthermore, although combined medication and psychotherapy is the most common treatment practice for veterans with PTSD, 7 current guidelines are unable to make specific recommendations. 8 The few extant comparisons of trauma-focused psychotherapy vs SSRIs or combined treatment have significant limitations in design or generalizability or have focused on refractory conditions or augmentation strategies.
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The present study was designed to address these critical gaps in guidance for clinicians, especially those who serve military service members and veterans. The study provides a comparison of 2 effective treatments for PTSD-prolonged exposure therapy and sertraline hydrochloride-and whether their combination enhances either treatment alone. Prolonged exposure therapy was selected owing to the abundance of research supporting its efficacy. 1, 15 Of the 2 SSRIs approved by the US Food and Drug Administration for the treatment of PTSD, 1 sertraline is generally tolerated better than paroxetine hydrochloride and has more robust data on long-term efficacy. 5, 16 To control for placebo effects and nonspecific effects of therapy (eg, therapist alliance or consistency of administration), prolonged exposure therapy was combined with pill placebo or sertraline (double-blinded), and sertraline was administered using a manualized enhanced medication management protocol. 17 In this context, sertraline and prolonged exposure therapy plus sertraline were administered under matched conditions, with psychotherapists and pharmacotherapists administering treatment modalities according to manualized protocols, under expert supervision. We examined the relative efficacy of prolonged exposure therapy plus placebo, prolonged exposure therapy plus sertraline, and sertraline plus enhanced medication management among 223 veterans with combat-related PTSD on our primary outcome of PTSD severity as assessed by blinded clinicians 18 and on our secondary outcomes of clinically meaningful change, remission, response, and self-reported PTSD.
19
Based on previous studies, 20 we hypothesized that larger reductions in symptom severity would be achieved with prolonged exposure therapy plus sertraline than with prolonged exposure therapy plus placebo and that larger reductions in symptom severity would be achieved with prolonged exposure therapy plus placebo than with sertraline plus enhanced medication management. Finally, based on concerns that sertraline might interfere with learning and reducing symptom severity using prolonged exposure therapy, we hypothesized that treatment dropout in the group treated with prolonged exposure therapy plus sertraline would be greater than in either the group treated with sertraline plus enhanced medication management or the group treated with prolonged exposure therapy plus placebo.
Methods

Design
The Prolonged Exposure and Sertraline Trial (PROGrESS) is a randomized clinical trial approved by the institutional review boards at the Veterans Affairs Ann Arbor Healthcare System, the Veterans Affairs San Diego Healthcare System, the Ralph H. Johnson Veterans Affairs Medical Center, and the Massachusetts General Hospital Home Base Veterans Program and the Department of Defense Human Research Protection Office. The study is registered at ClinicalTrials.gov, and the trial protocol is available in Supplement 1. A data safety and monitoring board reviewed the conduct of the study. Participants provided written informed consent before enrollment. Participants and clinicians were blinded to pill condition through week 24, and independent evaluators were blinded to treatment assignments for the duration of the study.
Participants
Participants were recruited from the following 4 sites: the Veterans Affairs Ann Arbor Healthcare System, the Veterans Affairs San Diego Healthcare System, the Ralph H. Johnson Veterans Affairs Medical Center, and the Massachusetts General Hospital Home Base Veterans Program. Inclusion criteria were service members or veterans of the Iraq or Afghanistan wars with combat-related PTSD and significant impairment (Clinicians-Administered PTSD Scale [CAPS] 5 score, ≥50) of at least 3 months' duration. Exclusion criteria were the following: (1) current, imminent risk of suicide; (2) active psychosis; (3) alcohol or substance dependence (in the past 8 weeks); (4) inability to attend weekly appointments for the treatment period; (5) prior intolerance to or failure of adequate trial of prolonged exposure therapy or sertraline; (6) medical illness likely to result in imminent hospitalization or contraindication to study treatments; (7) serious cognitive impairment
Measures
Self-report and clinician-administered clinical measures occurred at weeks 0 (intake), 6, 12, 24, 36, and 52. Blinding was broken at week 24. The primary outcome was severity of PTSD symptoms in the past month measured by the CAPS, 5 a clinician interview assessing symptom severity and diagnostic status. Current severity of PTSD symptoms was assessed in relation to targeting the most distressing war zone trauma. The DSM IV-TR CAPS version 22 was used, as the DSM-5 23 was not available at study initiation.
The secondary outcome was self-reported symptoms of PTSD (PTSD Checklist [PCL] Specific Stressor Version), 19 clinically meaningful change, response, and remission. Clinically meaningful change was defined as a reduction of 20 points or more in the CAPS score or a CAPS score of 35 or less, response was defined as a reduction of 50% or more in CAPS score, and remission was defined as a CAPS score of 35 or less; all definitions are based on week 24 or last observed CAPS score up to week 24.
Treatment
Active treatment began at week 0 and was maintained through week 24. Sertraline therapy was titrated through week 10 and continued until week 24. Early response was defined as 2 consecutive PCL scores below 28. Enhanced medication management elements ended at week 12 or with early response. Previous investigations 24, 25 and recent evidence 26 support these criteria, documenting 18% of individuals with militaryrelated PTSD as early responders to prolonged exposure therapy.
Prolonged Exposure Therapy
Participants were scheduled for 13 standard, 90-minute prolonged exposure therapy sessions by week 12 and were allowed to complete all sessions by week 24. Prolonged exposure therapy sessions included recorded sessions and in vivo exposure homework. 27 All study therapists were trained with a Veterans Affairs prolonged exposure therapy 4-day workshop and demonstrated fidelity on at least 2 supervised cases. Prolonged exposure therapy fidelity was ensured via structured weekly supervision telephone calls and independent audio recording of a random 20% of sessions (381 sessions). The therapy staff were 15 certified therapists across 4 study sites (3 from the Veterans Affairs Ann Arbor Healthcare System, 2 from the Veterans Affairs San Diego Healthcare System, 5 from the Ralph H. Johnson Veterans Affairs Medical Center, and 5 from the Massachusetts General Hospital Home Base Veterans Program). The mean (SD) number of prolonged exposure therapy cases per therapist was 8.7 (7.7) (median number, 6; range, 1-30). The analyzed fidelity measure consisted of 22 items per session, assessing prolonged exposure therapy components and therapist behaviors, and components or prescriptions not related to prolonged exposure therapy. All sites achieved a mean fidelity per session of at least 94%.
Pharmacotherapy
Medication doses were flexibly adjusted between 50 and 200 mg/d, with the last dosage increase at week 10 to ensure stable dosing by week 12. Medication was continued until week 24. Medication management (sertraline or placebo) was fully manualized to standardize pharmacotherapy delivery as brief (approximately 15 minutes) medication management, when administered alongside prolonged exposure therapy, or as enhanced medication management. Enhanced medication management was approximately 30 minutes for those randomized to receive sertraline alone to balance time, psychoeducation, and clinician support compared with prolonged exposure therapy conditions. 17 Thus, enhanced medication management added 15 minutes of psychoeducation and/or active listening to the 15-minute routine medical manage-comparisons of interest.
To compare week 24 outcomes and pace of recovery, we used a mixed model of repeated measures with week 0, 6, 12, and 24 assessments as dependent variables, and with indicators for sertraline plus enhanced medication management and for prolonged exposure therapy plus sertraline, ln (time), interactions of ln (time) by indicators for sertraline plus enhanced medication management and for prolonged exposure therapy plus sertraline and study sites (stratification factor) as predictors. In the CAPS model, log-transformed time was used to model nonlinear slopes of time, and the interaction term of ln (time) by group was used to test for treatment effects on the rate of symptom changes over time. The model included random intercepts and slopes with autoregressive covariance structure, and, based on the model, predicted mean CAPS scores at week 24 were compared between 2 pairs of treatment groups. We examined the extent and pattern of missing data and used logistic regression model to evaluate baseline factors predictive of missing week 24 CAPS score and included them as covariates in sensitivity analysis. For the PCL, polynomial terms of time were included to model curvilinear trends. We examined adherence to treatment assignment (retention), with adherence to medication defined as taking medication or placebo at week 24, and adherence to prolonged exposure therapy defined as completing 13 therapy sessions within 24 weeks. Early responders were considered adherent to treatment. Treatment adherence was defined for combination therapy (eg, prolonged exposure therapy plus placebo) as completion of both therapies. Binary outcomes included remission, response, and clinically meaningful change, and they were compared across treatment groups using logistic regression models, adjusting for site, baseline CAPS score, and sex. Figure 1 shows the CONSORT diagram; 472 participants underwent eligibility assessments after providing informed consent, 223 were randomized, and 207 participants (33, 34, 95 , and 45 at each of the 4 sites) were dispensed medication (primary intent-to-treat cohort). After flexible dosage titration to tolerability and response, the mean (SD) week 12 sertraline hydrochloride dosage was 170.7 (46.9) mg/d for the sertraline plus enhanced medication management group, 171.6 (45.0) mg/d for the sertraline plus prolonged exposure therapy group, and 197.4 (11.3) mg/d for the prolonged exposure therapy plus placebo group (P < .001). The week 12 dosage for prolonged exposure therapy plus placebo differed from the 2 sertraline groups combined (P < .001). As previously noted, concurrent treatment with antidepressants or antipsychotics, benzodiazepines, prazosin, or sleep agents (eg, zolpidem) was allowed if the dosage was stable for 2 weeks. At baseline, the difference in concomitant psychiatric medications was significant across groups: allowed psychiatric medications at stable dosages were present in 9 of 71 patients (12.7%) in the sertraline plus enhanced medication management group, 20 of 67 patients (29.9%) in the prolonged exposure therapy plus placebo group, and 16 of 69 patients (23.2%) in the sertraline plus prolonged exposure therapy group (P = .04).
Results
Modified Intent-to-Treat Cohort
Patient characteristics were comparable across groups, except for sex, marital status, and baseline function ( Table 1) . The prolonged exposure therapy plus sertraline group had fewer men and fewer married participants. Completion of week 24 CAPS did not differ significantly across treatment groups (56 of 71 [78.9%] in the sertraline plus enhanced medication management group, 42 of 67 [62.7%] in the prolonged exposure therapy plus placebo group, and 51 of 69 [73.9%] in the sertraline plus prolonged exposure therapy group; P = .10).
Unadjusted descriptive statistics of primary and secondary outcomes are shown in Table 2 , and unadjusted mean crosssectional CAPS scores are shown in Figure 2 .C h a n g e si n unadjusted CAPS scores showed significant symptom reductions at week 24 (33.8 points for sertraline plus enhanced medication management [P < .001], 32.7 points for prolonged exposure therapy plus sertraline [P < .001], and 29.4 points for prolonged exposure therapy plus placebo [P < .001]). The primary model of longitudinally assessed CAPS scores showed no significant difference at week 24 between prolonged exposure therapy plus placebo and sertraline plus enhanced medication management (mean [SD] difference in score, 9.11 [4.65]; P = .05) or between prolonged exposure therapy plus placebo and prolonged exposure therapy plus sertraline (mean [SD] difference in score, 6.69 [4.77]; P = .16) ( Table 3) ; the predicted mean scores were 41.9 for the sertraline plus enhanced medication management group, 51.0 for the prolonged exposure therapy plus placebo group, and 44.4 for the prolonged exposure therapy plus sertraline group. The symptoms of PTSD decreased significantly (β, -9.39; 95% CI, −11.62 to −7.16; P < .001) over 24 weeks in the prolonged exposure therapy plus placebo group, and the rate of the decrease in the CAPS scores did not differ significantly for the sertraline plus enhanced medication management group (β, -0.98; P = .52) or for the prolonged exposure therapy plus sertraline group (β, -0.60; P = .70) (Table 3; Figure 2) .
Secondary outcomes of self-reported symptoms of PTSD (PCL) estimated from a mixed model of repeated measures did not differ significantly across groups (eFigure in Supplement 2). The predicted mean difference in PCL scores at week 24 was 0.01 between the prolonged exposure therapy plus placebo group and the sertraline plus enhanced medication management group (P = .99) and 2.6 between the prolonged exposure therapy plus placebo group and the prolonged exposure therapy plus sertraline group 2.6 (P = .28).
Sensitivity Analysis
Missing data for the week 24 CAPS scores occurred for 15 of 71 participants (21.1%) in the sertraline plus enhanced medication management group, 25 of 67 participants (37.3%) in the prolonged exposure therapy plus placebo group, and 18 of 69 participants (26.1%) in the prolonged exposure therapy plus sertraline group. Missing data were associated with race/ ethnicity and marital status, and the primary model of CAPS, adjusting for marital status and race/ethnicity, did not show a difference in the week 24 outcomes by treatment groups. The dropout rate from the blinded study medication was 26.8% (19 of 71) for the sertraline plus enhanced medication management group, 47.8% (32 of 67) for the prolonged exposure therapy plus placebo group, and 40.6% (28 of 69) for the prolonged exposure therapy plus sertraline group, with a median time of discontinuation of therapy of 12 weeks for the sertraline plus enhanced medication management group, 5 weeks for the prolonged exposure therapy plus placebo group, and 5 weeks for the prolonged exposure therapy plus sertraline group. The dropout rate was 47.8% (32 of 67) in the prolonged exposure therapy plus placebo group and 42.0% (29 of 69) in the prolonged exposure therapy plus sertraline group, with a median time of discontinuation of prolonged exposure therapy of 5 weeks in both groups. Adherence (retention) to the entire treatment condition (ie, both the prolonged exposure therapy and the pill for the prolonged exposure therapy plus placebo group and the prolonged exposure therapy plus sertraline group) differed across groups whether unadjusted or adjusted, with the highest rate of adherence in the sertraline plus enhanced medication management group (52 of 71 [73.2%]), and the lower rates of adherence in the prolonged exposure therapy plus placebo group (31 of 67 [46.3%]) and the prolonged exposure therapy plus sertraline group (37 of 69 [53.6%]) (unadjusted P = .005 and adjusted P = .006). Similar to the primary modified intent-to-treat analysis, sensitivity analysis examining the adherent subset found no differences in CAPS scores by treatment group.
Clinically Meaningful Change, Response, and Remission Outcomes
None of the dichotomized response (χ 2 = 2.07; P = .36), clinical response (χ 2 =1. 37 ;P = .50), and remission (χ 2 = 3.43; (Table 2) after adjusting for site, baseline CAPS score, and sex.
Discussion
This head-to-head randomized clinical trial comparing sertraline plus enhanced medication management, prolonged exposure therapy plus placebo, and prolonged exposure therapy plus sertraline was initiated to answer fundamental questions about the efficacy of these treatments alone or in combination in a population of veterans. All treatments led to significant reductions in the severity of PTSD symptoms. However, contrary to our hypotheses and findings in metaanalyses, no significant differences were observed across the 3 study groups in severity of PTSD symptoms for either clinician-assessed measures or self-report measures. These results are unlikely to be the result of type II error because the study was well powered for these comparisons. The high rates of clinically meaningful change observed among veterans in this trial (eg, ranging from 52% to 62%) are noteworthy, given the proportion of participants with chronic treatmentresistant PTSD. There were no significant differences in response rates or remission rates across treatment groups. Although we hypothesized greater effects for combination treatment than for either treatment alone and greater effects for prolonged exposure therapy plus placebo than for sertraline plus enhanced medication management, the results that we observed were not entirely unexpected. A previous randomized clinical trial of eye movement desensitization and reprocessing vs fluoxetine showed no differences 12 weeks after treatment, 12 and a study comparing a hybrid traumafocused exposure-based acceptance and commitment therapy and medical management (sertraline supplemented with a sleep aid), or their combination, showed no significant differences after treatment. 9 Finally, prolonged exposure therapy resulted in statistically higher rates of remission of PTSD compared with paroxetine, but the combination of prolonged exposure therapy and paroxetine did not differentiate from either alone.
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Importantly, this study was designed to deliver sertraline and prolonged exposure therapy plus sertraline under matched conditions that included rigorous training and ongoing supervision of psychotherapists and pharmacotherapists. To balance clinical attention and expectations, the group receiving sertraline without prolonged exposure therapy received 30 minutes of enhanced medication management, with sertraline expected to support medication adherence. 1 These enhancements may have contributed to the somewhat larger effect size obtained for the sertraline plus enhanced medication management condition compared with previous medicationonly trials. The present study did not include a prolonged exposure therapy without a pill condition, which resulted in increased patient burden during prolonged exposure therapy in clinical practice. Thus, the quality of the prolonged exposure therapy provided was high, but the overall effect may have been affected by the placebo. Moreover, we used 24 weeks as our primary outcome, with high levels of adherence to medication and a graded 10-week titration schedule to minimize adverse effects. This longer duration of medication management may have allowed participants to achieve greater benefit from sertraline compared with shorter trials, as previous studies have shown.
28
Contrary to our hypotheses, while sertraline plus enhanced medication management performed better than expected, in the purist effectiveness comparison of prolonged exposure therapy plus sertraline vs prolonged exposure therapy plus placebo, there was no evidence for added benefit for active medication. It is possible that participants in both the prolonged exposure therapy plus placebo group and the prolonged exposure therapy plus sertraline group attributed changes to the pill, reducing motivation for exposure components. The combined prolonged exposure therapy treatments had a greater burden for participants owing to the requirement to attend 2 different appointments and more time required per week in addition to homework, which may have contributed to the higher attrition among the participants who received prolonged exposure therapy compared with the participants who received sertraline alone. The present study design allowed for early response, and the prolonged exposure therapy plus sertraline group did show significantly more early responders (13 of 69 [18.8%]) than did the other 2 groups (6 of 67 participants [9.0%] in the prolonged exposure therapy plus placebo group and 4 of 71 participants [5.6%] in the sertraline plus enhanced medication management group were early responders). However, the overall slopes of change and the results of the intent-to-treat analysis did not differ. There were significant differences in rates of adherence, with adherence being lower in both the prolonged exposure therapy plus sertraline group and the prolonged exposure therapy plus placebo group.
Limitations
Although our results are informative, limitations are apparent. Based on study design, only combat veterans were included, suggesting that an extension to other trauma populations and demographic groups that are not represented is necessary. In addition, only participants who were not currently taking an SSRI and were willing to receive prolonged exposure therapy and/or sertraline could be randomized. This restriction made recruitment challenging because many veterans with PTSD were already receiving an SSRI, 7 and many a The model is based on CAPS scores at weeks 0, 6, 12, and 24 and had random intercepts and slopes with autoregressive covariance structure. The CAPS score was also evaluated using longer-term data by including weeks 36 and 52 and no differences in slope were found across groups (P = .83).
b Time is in weeks and log-transformed to depict the pattern of decreasing symptoms at a decreasing rate seen in Figure 2 . Coefficients of ln (time + 1) estimate the treatment effect as changes in symptom scores, and they do not differ between sertraline hydrochloride plus EMM vs PE plus placebo (P = .52) and between PE plus sertraline vs PE plus placebo (P = .70).
c The standardized effect sizes based the between-group difference in CAPS scores are 0.38 (9.11/23.7) for PE plus placebo vs sertraline plus EMM and 0.28 (6.69/23.7) for PE plus placebo vs PE plus sertraline, where 23.7 is the common SD of the changes in CAPS score from baseline to week 24.
veterans are unwilling to take psychotropic medication. 29 Third, the enhanced medication management protocol is not standard medication management but does show excellent results. This protocol may provide a possible guide to enhance routine medication treatment and achieve the magnitude of effect found in this study.
Conclusions
In this first direct comparison of 2 of the most commonly administered treatments of PTSD (sertraline and prolonged exposure therapy) and their combination (sertraline plus prolonged exposure therapy) for veterans, we found no significant differences between the 3 treatment groups. These results require additional replication and may suggest changes to future clinical guidelines, particularly when SSRIs are administered under similar conditions to this study. intervention to whom and when to combine the treatments. As a result, treatment is most often guided by than the current study will provide (i.e. ~300 PTSD patients treated with SERT and 300 with PE including those 137 who receive the combination treatment). However, our proposed study is the largest treatment response study 138 in PTSD in combat veterans to date to collect these data, and will provide an outstanding opportunity to 139 develop an initial "discovery" dataset, which can be replicated in validation cohorts. While the current 140 cohort is not sufficiently powered for genome-wide association study (GWAS), the incremental costs associated 141 with collection of deoxyribonucleic acid (DNA) and genome-wide genotyping are relatively small compared to 142 the costs of obtaining the psychiatric treatment phenotype. The benefit of having these GWAS data on our
143
initial discovery dataset (with high quality phenotypic and genotypic measures) archived and available for 144 immediate delivery to partners with subsequent replication cohorts will be highly valuable to the field of PTSD 145 treatment research.
146
In addition to prediction of response by genetic variations, changes in brain gene expression may also as genes implicated in PTSD pathophysiology.
296
3) Treatment will be associated with changes in leukocyte gene expression (mRNA) profiles.
297
a. SERT will lead to specific changes in mRNA expression related to primary pharmacological effects. efficiency. In the end, improved treatments will allow more troops to efficiently return to duty and reduce
368
PTSD related disability.
370
Public Purpose
371
Our proposed study will examine the comparative efficacy of PE/PLB, SERT, and PE/SERT and 372 provide an in depth examination of predictors of response and mechanisms of change in PTSD treatment.
373
Understanding the relative benefits of these interventions and their mechanisms is equally critical for military Reappraisal Task). In addition, bi-weekly self-report assessment of symptoms (PTSD, depression, and anxiety) 403 will be completed. While our primary aim will focus on symptom change, we will also examine differential 404 drop out/early response and treatment adherence. all Veterans who appear to meet eligibility criteria will provide a urine screen (ONLY after fully reviewing the 411 study consent and Form 10-3203) for a drug and pregnancy screen. The urine will be provided based on Mental
412
Health Service Standard clinic protocols for urine toxicology and pregnancy screens in the patient facility.
413
Those Veterans who have a positive pregnancy screen will not be eligible for the study due to the and post-deployment health reassessment (PDHRA) roster. The letter will include general information regarding this research study, which will be applicable for both treatment eligible participants and combat 433 controls (CC).
434
• Posting study flyers on IRB approved websites such as Facebook, Twitter, Reddit and Craigslist. Flyers will
435
have URL-shortened links and QR codes that direct those interested to our approved VAAAHS study 436 webpage for more information about participation.
437
• Promotional swag (i.e., mugs, post-it notes) with the study logo and contact information are also used as a 438 recruitment tool and only given out to providers who may come into contact with potential participants
439
• IRB approved public service announcements
440
Potential participants (participants with and without PTSD) who express an interest in the study will initially 441 complete the phone screen. If they qualify at that point, they will be invited for a meeting at the VA.
442
Feasibility of recruitment. were married and 15% divorced or separated. 88% were Caucasian, 7% African American, and 5% other.
446
Sixty-one percent met criteria for current major depressive episode and 25% met criteria for alcohol abuse. Of 447 139 subject, 122 (88%) would meet the minimal inclusion and exclusion criteria for this study. Given these 448 numbers and assuming a 50% recruitment rate we expect up to 5 veterans consented per month. Thus,
449
recruitment goals should easily be met. criteria. Given the minimal exclusion criteria, a majority of these veterans will be eligible for the 466 study. Assuming a 50% recruitment rate, we expect 2-4 veterans consented per month at this site.
467
Screening data including drop at all possible points will be collected in order to meet requirements of 2) ferrous containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles), and 3) inability 504 to tolerate small, enclosed spaces (e.g. claustrophobia) 4) Patient girth exceeds allowable fMRI machine dimensions.
505
Eligible veterans will be offered the study and those who agree to participate will review consent documents 506 with study staff (see consent below).
508
To be included as a subject in the Combat Control (CC) group, the following CC Inclusion criteria must be met: we can obtain for a multi-site trial. Participants will be block randomized by site with central distribution of 519 randomized condition from the MICHR study staff to the study coordinator for PE status and to the study 520 pharmacist at the facility for pill status. This will ensure that blind is maintained. Randomization will be based 521 on a computer generated table of random numbers. MICHR will be responsible for providing these 522 randomizations at the time of consent. Once eligibility is determined as part of the standard intake in the clinic,
523
those returnees who meet inclusion and exclusion criteria and are interested will review study consent procedures as appropriate. Major study assessments will occur at Intake Week, Weeks 6, 12, 24, 36, and Wk 52.
530
These assessments will include interview and self reports of symptoms and function (see Table 1 ). In addition,
531
neurobiological assessment (salivary cortisol RTA) will occur at all major assessments (except Intake Week) and Week 0. Blood draws for genetics and genomics will occur at Week 0 (or within 7 days prior to) and Wk 533 24. Participants will receive $50 for each major assessment visit completed at Intake Week, Wk 6, 12 and 24. .
534
Participants will receive $75 for a completed Week 36 major assessment visit and finally $100 for a completed
535
Week 52 major assessment visit All fMRI component participants will receive $100 for each fMRI study scan 536 completed. In addition, participants traveling to Ann Arbor to complete the fMRI study will receive $700 per 537 day and travel expenses, including hotel, flight, ground transportation, and GSA set per diem ($42/per day).
538
The study will require one day for travel to Ann Arbor. We will scan on Day 2 and return travel home day 2 539 whenever possible. For any participants who are active duty, payments will be discussed in order to ensure they 540 do not receive payments when on-duty. Combat control participants will receive $50 for completion of the 541 interview procedures and $100 for completion of the fMRI scan. All intakes and interview measures will be 542 completed by the independent evaluator (IE) blinded to treatment assignment and trained in both the MINI and
543
CAPS. Interviews will be audiotaped for use in recalibration and interrater reliability assessment. All IEs will 544 complete bi-monthly recalibration assessment reviews for CAPS and yearly MINI recalibration assessment 545 reviews. In addition to the assessments listed below, the evaluator will collect comprehensive information 546 regarding past and current treatment (medication and psychotherapy). All self-report measures will be 547 accessible on-line for those veterans who choose to complete them through the secure Velos server using their 548 secure password and research identification. This will allow flexibility for the participants and will also be 549 available for participants who do not follow through on study protocol so that information on their status as well and receive alternate care outside of the study in outpatient psychiatry. The consent process will take place at 562 the identified site where the participant completed their intake. Participants will be afforded as much time as 563 they need to make a decision regarding their desire to participate in the study. Additionally, study staff will 564 provide contact information and will be available to discuss any questions or concerns potential participants 565 may have. If the patient decides he/she would like to participate more than four weeks after their intake 566 assessment in the clinic, inclusion and exclusion will be reviewed again prior to consent. No study procedures 567 will be conducted prior to obtaining consent. The fMRI portion of the study will be discussed after completing 568 consent for the main study. The study staff member will review the participant's interest and the additional 569 exclusionary criteria for the fMRI. The consent will then be reviewed and the participant signature will be 570 obtained if they understand and agree. This will occur at all sites for all patients consented until the recruitment 571 goal for the fMRI procedures (n = 210) is reached. All subjects will complete consent prior to any scheduling 572 of travel and the consent will be reviewed again prior to the scan.
573
Patient Randomization. Study subjects will be block randomized by site with central distribution of 574 randomized condition from the MICHR study staff to the study coordinator for PE status and to the study 575 pharmacist at the facility for pill status. This will ensure that blind is maintained. Randomization will be based 576 on a computer generated [95]. Alcohol use questions concern the number of days of alcohol use, the average consumption per drinking 656 day, the maximum consumption, and the number of binge days (days that more than five drinks were 657 consumed). The SAOM also examines substance use for various recreational drugs (e.g., marijuana, cocaine or 658 crack, prescribed stimulants, heroin, anabolic steroids, and tobacco). The CC group will have the same assessments described above at the Intake session. They will not have 706 repeat assessments and will not undergo any interventions described below.
707
Interventions. Participants will complete up to 13 weekly sessions of the randomly assigned treatment with 12 be provided either through referral or care outside of the study. Whether study assessment will be continued will 718 be determined in the best interests of the patient. Veteran already has a Safety Plan, it will be reviewed at each additional visit where significant risk of self-harm is 783 reported (items 3, 4, or 5 are endorsed). The need for study treatment termination will be determined on a case-by-case 784 basis in coordination with the care team, site PI, and study PI. However, no prohibition against necessary treatment will be 785 in place if needed. Abrupt discontinuation of SERT can also be associated with withdrawal symptoms, such as 786 depressed mood, irritability, moodiness, dizziness, pins and needles feelings, anxiety, confusion, headache, 787 sluggishness, nightmares, vertigo, vomiting, tremor, and insomnia. Thus, a gradual reduction in dosage rather 788 than abrupt discontinuation will be highly recommended for any individuals wishing to stop study medication.
789
Patients will also be asked to contact the investigator before discontinuing the study medication to discuss their 790 concerns and to devise an appropriate plan. Placebo medication will be used in this study because there is a 791 need to establish the relative effect of PE without SERT pharmacotherapy compared to combination treatment.
792
All participants in this study receive at least one intervention with previous demonstrated efficacy for PTSD (PE 793 and/or SERT).
794
Placebo capsules (PLB) will be used in this study because there is a need to establish the relative effect 795 of PE without SERT pharmacotherapy compared to combination treatment. The PLB is composed of 796 microcrystalline cellulose and poses no additional risk. PLB capsules will be prepared using size #0 gelatin 797 capsules, filled entirely with microcrystalline cellulose. A bulk supply of PLB capsules will be prepared using a 798 single lot of microcrystalline cellulose and will be labeled with contents (PLACEBO capsules), date of 799 manufacture, lot number and expiration date. PLB capsule expiration dating will be 12-months from date of 800 manufacture or the lot-specific expiration date of the microcrystalline cellulose filler, whichever occurs first. initiate double-blind sertraline at week 0 with 25 mg/day followed by a dose increase to 50 mg/day at week one.
824
If patients are unable to initially tolerate 50 mg/day they will be permitted to remain at 25 mg/day during week 825 1, but the dose must be titrated to 50 mg/day by week 8. If no slowing of dose titration is required, at week 4 826 the blinded sertraline dose will be raised to 100 mg/day. Thus, for a patient with no significant side effects or 827 slowing of titration dosing will be 25 mg at week 0, 50 mg at week 1 and 100 mg at week 4, 150mg at week 6 828 and 200mg at week 8 (as summarized in Table format Use of the CGI-S and Side Effect Monitoring Scales are Summarized below but discussed in more detail at
842
Visit 1 (see page 20).
843
Use of CGI-Severity and Side Effect Monitoring to Guide Dosing Decisions:
844
• Specifically, if the CGI severity rating is greater than 2 (borderline ill), and the side effect burden 845 is low, the dose is increased per schedule.
846
Use of the FIBSER as a Starting Point for Side Effect Guidelines for Dosing: The FIBSER will be used as a 847 guide in side effect assessment and dosing decisions at every visit.
848
• A FIBSER score of 5 or more should trigger extra attention to side effect monitoring and review
849
• A score of >7 on the FIBSER will signal no increase in dose, although specific side effects should be 850 reviewed in detail before a final determination and a dose increase may occur with justification for 851 increasing the dose. If the dose is not increased because of side effects, the pharmacotherapist should 852 continue to evaluate for possible increase at each subsequent visit.
853
If medication dose is held or decreased beyond these outlined adjustments, the reason for doing so must 854 be clearly documented on the deviation record. All such deviations must be approved by the overall study 855 pharmacotherapy supervisor (Dr. Simon). completed as required. Review of medical history and laboratory tests will be performed at admission.
890
Test Article Dispensing and Accountability
891
All of the following is pulled from the VAAAHS Pharmacy Investigation Drug Handling Policy (119-04) and 892 applied to our test article (SERT/PLB).
893 894 a. SERT/PLB is approved as a test article and identified in the VA Drug File as a study medication. Two separate, 895 study-specific Drug File entries will be made: SERT25/PLB STUDY DRUG and SERT50/PLB STUDY DRUG. The 896 SERT25/PLACEBO entry will only be used during the first week of titration (week 0). The SERT50/PLACEBO entry 897 will be used for the remainder of the titration period and for maintenance therapy to minimize the number of capsules 898 necessary to achieve a target dose of 200 mg. Study subjects who do not tolerate the dose increase at week 1 (50 mg) 899
will be down-titrated to SERT25/PLB. 900
(1) An investigational drug log (automated or written) authorized by the facility or clinical investigation sponsor 954 must be maintained and contain the following information: 955 (a) Name of the drug, dosage form, and strength. (n) Date the protocol was approved.
969
(o) A final entry is made when drug therapy for the entire study (at the site) has ended. This entry documents 970 the date of termination of the use of the drug, the quantity remaining, the action taken to dispose of the balance on hand 971 and the agent or individual responsible for drug destruction or return.
972
(2) All entries will be checked and initialed by a pharmacist. 973 974
Neurobiological measures. allowing minimal processing at phlebotomy sites. Blood will be shipped to the central repository at VAAAHS via overnight courier, archived in LIMS, and stored at -20C. Whole blood contains multiple leukocyte cell 005 species; the majority globin mRNA can interfere with measurement of leukocyte mRNA and will be removed 006 ("GLOBINClear, Ambion). RNA yield and purity (260 nm:280 nm) will be determined using NanoDrop, and 007 integrity of total RNA using Agilent Bioanalyzer 2100. Anti-sense RNA will be synthesized and hybridized to button press (see Figure 6 ). The stimulus set will 3. Visual-Motor Task (VMT): Each subject will perform a well-validated task to selectively and reliably 091 activate primary motor and visual cortex (M1 and V1, respectively). In brief, the activation task consists of 092 visual stimulation using a flashing checkerboard pattern at 10 Hz ("on" blocks), and interspersed by periods of 093 rest ("off" blocks) where subjects view a blank screen/fixation crosshair; subjects are instructed to press their 094 right (e.g., dominant) index finger on the button press rhythmically during "on" blocks and remain motionless 
Resting State Task (RST):
In this task, subjects are instructed to simply "rest, try to empty your mind,
099
and relax" while maintain their head still and looking at a blank screen for about 8 minutes. Patients will be instructed to refrain from eating, drinking, brushing their teeth, or smoking for at least one hour 105 before sampling. They will bring the samples to the laboratory that day. Assays will be performed in Dr. bring the samples to the site on the day of the major assessment (except Intake Week) and at Week 0.
121
No processing of the saliva samples is required at remote sites. Saliva specimens, with bar-coded labels, will be 122 turned in to study staff at each site upon collection, and temporarily stored at each site in freezers until they are 123 shipped to VAAAHS. Each site will maintain an electronic collection tracking "log" containing tracking 124 information including subject ID number, follow-up, and date of specimen collection and date of storage, and 125 other meta-data as necessary (e.g. missing tubes, mistakes, etc.). This information will be stored in the patient 126 tracking database on the secure server at each site. Periodically, saliva specimens will be shipped to our be logged and specimens inspected, and each will be logged into our laboratory information management 133 system (LIMS) using barcode, and specimen tubes transferred to freezers until time of assay (see assay section) 134 at which time they will be centrifuged and saliva used up.
136
B. Blood for DNA and RNA: Blood samples will be obtained from patients at each site at Week 0 (or 7 days 137 prior to) and again at post treatment (Wk 24). Blood will be drawn in morning (after overnight fast), collected 138 in two separate collection tubes: 3 ml blood for RNA collected in a RNA collection tube (tempus) and 10ml 139 blood for DNA and cortisol collected in a purple capped EDTA collection tube (vacutainer). The collection 140 tubes will have bar-coded labels, containing subject ID and follow-up time-point, and each site will also 141 maintain a "tracking log" containing data such as subject ID and time-point, and other relevant meta-data (time 142 and date of collection, technician, date of shipping, etc.) but no PHI. At each site, the RNA tubes will be 143 shaken vigorously or vortex for 10seconds. For DNA and cortisol, each site will spin the tube in a centrifuge, 144 aspirate the plasma into a fresh, appropriately labeled tube for cortisol. They will then save the RBC pellet in 145 the original collection tube for DNA. For RNA: Store the RNA tempus tubes at room temperature until used.
146
For DNA and cortisol: The plasma and RBC pellet samples will be stored in a box on-site in a freezer until 147 being shipped. Blood will be shipped to the central repository at VAAAHS via overnight courier at room 148 temperature. Blood is classified as a biohazard, and therefore appropriate DOT approved shipping methods will 149 be used for biohazard, including containment and absorbent materials, etc. Shipping will be done Mon -
150
Thursday, and email notification will be made to the lab at time of shipping, including tracking numbers and 151 ETA, etc. Upon arrival in the VA Ann Arbor laboratory, the manifest and contents will be inspected, and each Tracking:
158 Each site will maintain an electronic collection tracking log containing tracking information including subject 159 ID number, follow-up, and date of specimen collection and date of storage, and other meta-data as necessary 160 (e.g. missing tubes, mistakes, etc.). This information will be stored in the patient tracking database on the secure 161 server at each site.
162
Packaging and Shipping:
163
For RNA: The RNA collection tubes will be shipped OVERNIGHT to our laboratory in VA Ann Arbor at room 164 temperature by UPS.
165
For DNA and cortisol: Periodically, the samples will be shipped to our laboratory in VA Ann Arbor for assay 166 and analyses. The tubes will be shipped frozen on dry ice by a commercial shipping company, with a detailed 167 manifest, including the above tracking information, since blood is classified as a biohazard, appropriate DOT 168 approved shipping methods must be used (i.e. containment and absorbent materials etc).
169
All samples will be shipped Monday-Thursday (Next Day Delivery), as long as WEEKDAY 170 DELIVERY TO LAB is assured.
171
Update the electronic collection tracking "log" with the date shipped.
172
Upon arrival at the VA Ann Arbor laboratory, the manifest will be logged and specimens inspected, and 173 each will be logged into our laboratory information management system (LIMS) using barcode. The plasma for 174 cortisol and RBC pellet for DNA and RNA tempus tubes will be transferred to freezers until time of assay.
176
Risks
177
Risks listed below may not apply to all patients if a patient is not involved with a specific procedure (i.e., not in 178 the fMRI portion of the study or a combat Veteran without PTSD who is not getting treatment). Specific risks 179 for the specific patient groups are covered in each relevant consent form for the patient at entry to the study.
180
Risks may include discomfort over touching the cotton when obtaining the saliva measure; discomfort, bruising, provider and/or the investigator before discontinuing the study medication.
215
For those patients who receive PE, increased distress may occur during therapy procedures. However, these 216 increases tend to decrease with continued treatment. Patients will be monitored for all side effects. All patients 217 will receive at least one active treatment (PE or SERT). As such, placebo does not involve additional risk.
219
All staff conducting interviews and study procedures have experience with PTSD populations. They will work 220 with the patient to reduce distress at the time of any exacerbations and will end procedures if in the best interest 221 of the patient. Patients will be made aware that they can request to end a procedure at any time and can choose 222 not to respond to interview or self report items if they choose. Blood will be drawn by trained personnel in a 223 resting position in order to minimize potential discomfort.
225
The Primary Investigator (PI) and other study staff and clinical care providers will be available should the 226 patient require additional assistance due to distress or side effects. procedure at any time. If the patient is not able to tolerate the procedure, the scan will be stopped immediately.
244
A mental health professional, associated with the study will be available to evaluate and discuss this experience 245 and the patients' reactions with them immediately, or if they prefer, at a later time. Because the strong electromagnetic fields can move metal objects and cause heating, there is a risk that loose 257 objects (jewelry, keys) outside your body could be accelerated by the magnetic field and strike patients, causing 258 you injury. There is also a risk that the magnetic fields could disturb a metal fragment in patients' bodies,
259
interfere with an implanted device, such as a pacemaker or neurostimulator, or cause metal (including foil-260 backed medication patches) on or in patients 'bodies to heat up, causing them harm. Study staff keep the 261 environment around the MRI scanner completely free of loose metal objects that could be moved by the 262 magnetic field, and we will make sure that patients have no metal on their bodies that could be affected by the 263 MRI scanner. We will also ask patients questions and have them complete an MRI screening form to make sure 264 that they have no metal inside their bodies that would cause them harm during the MRI scan.
266
There is the potential that a magnetic resonance image may reveal an abnormality that is already in a patient's 267 body, such as a cyst or tumor. The investigators on this project are not trained to find abnormalities on an fMRI 268 scan. We do not expect to report back to patients about any of the results from your fMRI scans. However, if we 269 believe that we have found a medical problem or something abnormal in a patient's fMRI scan, we will contact 270 the patient and will help him/her get medical follow-up for the problem. Many such abnormalities are not 271 clinically significant, but the patient may need or want to investigate them further. Such a finding might require 272 additional studies, and maybe even treatment, which would not be paid for by the investigators, the sponsor, or 273 the University of Michigan. The type of scans we will use are not very sensitive to many abnormalities. The 274 scanning procedures used for this study will not be read by a specialist trained to make medical diagnoses from 275 the scan. That is, even if there is an abnormality in a patient's body, it is likely that it would not be discovered by 276 the people who inspect the images. Therefore, it is likely that any abnormality that a patient may currently have 277 will not be revealed by the images obtained in this experiment. If a patient has any current health concerns, 278 he/she should consult his/her doctor. Discussion of this will occur during informed consent to ensure patient 279 understands that these research scans should not be used for clinical purposes.
281
Pregnant women will not be allowed to participate in the fMRI portion of this study. Urine pregnancy tests will 282 be performed. If this pregnancy test is positive, you will be removed from the fMRI portion of the study.
284
Data Management and Analyses
285
Data Management. All PHI will be managed within each site. This will include contact information 286 and protected electronic crosswalk files connecting returnee names to research ID numbers. All research data 287 will be identified by research ID only. All data with the exception of fMRI data will be remotely entered into to the database as data is verified by the site. In addition, standard reports will be provided to monitor site 296 performance, assess progress of the trial, and for safety reporting purposes. Upon completion of the study and 297 after resolution of any outstanding data issues, the database will be locked. Study project data can then be 
300
Copies of coded fMRI data will not be stored in the Velos database at MICHR, but will be transferred 
304
In addition, de-identified data may be sent to the other participating research sites (the VA San Diego
305
Healthcare System, VA Charleston Healthcare System, and Massachusetts General Hospital) for the purposes of 306 data analysis and dissemination. The information collected from the study is stored in a secure area and will not 307 be made a part of the subject's medical record. Subject's name or other personal identifier will not appear on 308 any of the research materials. All data is coded by research ID only. Only trained personnel with password 309 access will access data for purposes of processing and analysis.
310
Power Analysis. Our hypotheses are that all three interventions will be effective in reducing PTSD 311 related symptoms, with PE/SERT being most effective, followed by PE/PLB, and then by SERT. The study is 312 powered to detect outcome differences between the PE/PLB compared with SERT to directly assess the effect 313 of PE relative to sertraline, and PE/SERT compared with PE/PLB to assess the augmentation effect of SERT 314 to PE. We hypothesize that the effect sizes between the two comparisons to be similar; i.e., PE effect relative to 315 sertraline will be similar to the augmentation effect of sertraline to PE. CAPS scores will serve as the primary size as large as the assumed clinically meaningful effect size of 11.4 points, the proposed sample size will give 328 more than 90% power to detect pre to post treatment effect across all three intervention groups. across the groups at a 0.15 significance level will be included in the primary analysis as potential covariates.
339
Our primary hypothesis is that PE/PLB, compared with SERT, will result in larger reductions of PTSD, 340 general anxiety, and depression, larger increases in function and more remission, increases in cortisol in RTA, 341 and similarly for PE/SERT compared with PE/PLB. Primary outcome will be the change from baseline in 342 CAPS scores at Wk 24. Means and mean changes from baseline for each group as well as the mean difference 343 between pairs of each group will be reported, along with their 95% confidence intervals. The primary outcomes 344 will be compared using a linear mixed-effects model with the combined data from all three groups. A mixed-345 effects model is needed to address the potential within-therapist correlation, where we will include the therapists 346 as random effects. For SERT group patients, the pharmacotherapist providing the EMM will be considered as 347 the cluster. The model will include two indicators for PE/PLB group and PE/SERT group. The parameter 348 estimate of the PE/PLB indicator will estimate the effect of PE/PLB to SERT at Wk 24, and contrasting the 349 parameter estimates of the two indicators of PE/SERT and PE/PLB will allow us to estimate and test for the 350 effect of PE/SERT to PE/PLB. Though the patients are randomized into three groups, we will obtain covariate 351 adjusted estimate of the between group differences, in which the covariates will include baseline CAPS scores,
352
OEF/OIF/OND status, marital status, substance or alcohol abuse, and other baseline variables assessed to be potential confounders in the baseline analysis. Similar analyses will be done using other secondary outcome Non-adherence. While our primary aim will focus on symptom change, we will also examine differential 359 drop out/early response and treatment adherence. Our explorative hypothesis is that PE/SERT, compared with 360 either SERT or PE/PLB, will have more treatment drop. These comparisons will be made using treatment drop 361 as the response variable and using generalized linear mixed-effect model with logit link and two indicators for 362 the three treatment groups. The primary analysis will be done by intent-to-treat with participants retained in 363 their randomized groups regardless of their treatment adherence status. We will, however, also do additional as-364 treated analyses for which we will define the groups by the actual intervention each participant is randomized 365 to, but the outcomes will be censored at the time when participants switched or stopped the treatment to which 366 they were assigned. For participants in the PE/PLB or PE/SERT group, data will be censored at the time when 367 both therapy and medication (SERT or placebo) prematurely stopped. We note that in this study, if some 368 patients in SERT group stop or switch medication early due to side-effects or intolerance, as-treated analysis 369 may give a better outcome estimate for SERT group, thus likely to give an under-estimate of the PE effect 370 compared with the intent-to-treat analysis.
371
Missing Data. The extent of missing outcome values at each measurement times will be assessed by the 372 three study groups. Although we do not expect missing baseline values of more than 2 or 3%, we will assess the 373 amount of missing data in baseline covariates as well. If the extent of missing data are greater than 5% (we 374 conservatively assumed 30% to drop out of the assigned treatment, but we will make every effort to collect their 375 follow-up data), we will do sensitivity analysis of the effect where we will impute the missing data using a 376 multivariate sequential regression approach. The method can impute for nearly all types of data (binary, 377 categorical, count, and continuous) and imputes missing values for each individual conditional on all the values 378 observed for that individual, and thus exploits correlational structure among covariates that include all other 379 variables observed or imputed. We will then analyze the multiply imputed data to obtain outcome differences 380 between PE/PLB and SERT and between PE/SERT and PE/PLB, and examine for any substantive differences 381 in the conclusions based on the imputed data analysis versus the original data analysis.
382
Longitudinal Outcome Comparison. We will compare outcomes over the 12-month follow-up time in 383 order to have a good understanding of the pace of recovery and to compare retention trends after intervention.
384
We will plot cross-sectional means of various outcome measures at each measurement time as well as outcomes 385 over time for each individual to assess individual trends. We will use repeated measures mixed-effect model to 386 assess and compare outcome trends over time within each group as well as across the three groups. The 387 graphical exploration will guide the appropriate models describing the trajectory of outcomes, especially how 388 the time and the correlation within participants will be modeled. This analysis will allow us to assess when the 389 outcome differences occur and whether the differences remain over time using various ways to model time. In groups, we will model the trends separately for the three groups. Similar analyses will be done using other 392 secondary outcome variables.
393
Genetic Association with treatment response. DNA cleaning and Quality Control process described in 394 the Neurobiological Measures Supplement in appendix. We will investigate DNA markers as potential 395 predictors of treatment response ("pharmacogenetic" analyses) in subjects treated with SERT alone or together 396 with PE (n=294), and subjects treated with PE/PLB or PE/SERT (n=294). Since n=147 receive both treatments,
397
analyses of SERT will include "presence of PE" as a covariate, and vice versa. We will examine i) Replications 
